Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9907849
SERIAL NO

14802607

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MERCK SHARP & DOHME CORP126 EAST LINCOLN AVENUE RAHWAY NJ 07065-0900

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Mauro, David J Washington Crossing, US 15 212
Perini, Rodolfo F North Wales, US 3 51
Petit, Robert Newtown, US 71 847

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 6, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 6, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00